NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 2.790
- +0.140+5.28%
Close Mar 4 16:00 ET
- 2.920
- +0.130+4.66%
Post 20:01 ET
178.02MMarket Cap-2.43P/E (TTM)
2.840High2.522Low647.55KVolume2.630Open2.650Pre Close1.77MTurnover2.08%Turnover RatioLossP/E (Static)63.81MShares11.20052wk High0.90P/B86.84MFloat Cap2.52252wk Low--Dividend TTM31.13MShs Float664.320Historical High--Div YieldTTM12.00%Amplitude1.530Historical Low2.728Avg Price1Lot Size
Larimar Therapeutics News
Larimar Therapeutics | SCHEDULE 13G: Others
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BEN-MAIMON CAROLE
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Clayton Russell
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shankar Gopi
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Celano Michael
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | SCHEDULE 13G/A: Others
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Flynn James E